Press Release Details
Twist Bioscience Launches High Throughput Antibody Production Platform
-- Gene to Antibody Production Workflow Enables Customers to Turn Digital DNA Sequences into Purified IgG Antibodies --
In the antibody development pipeline, researchers often experience a bottleneck when transitioning from display library panning to antibody characterization. Antibody discovery platforms like phage-display and single B-cell sequencing make it possible to identify hundreds to thousands of potentially high-affinity antibodies for characterization and development. However, further study of these hits requires expression as full-length antibodies, a process that is often low-throughput, resource-intensive, costly, and a significant hurdle for advancement.
“The low-throughput, resource-intensive process of antibody variant characterization can be a costly bottleneck in the discovery pipeline. So, this unique offering, which provides the ability, in one place, to easily order gene sequences and receive the resulting antibodies, can make the timeline for antibody discovery and optimization programs more efficient. I’ve always said that Twist enables our customers to forgo the need to do cloning themselves, i.e. friends don’t let friends clone. Similarly, this new offering could have the same impact on high throughput antibody screening, i.e. friends don’t let friends make their own screening antibodies,” said Emily Leproust, Ph.D., CEO and co-founder of
The new offering will be highlighted at PEGS Boston (www.pegsummit.com), taking place
Twist High Throughput Antibody Production Workflow
The Twist High Throughput Antibody Production provides a comprehensive and efficient solution to antibody production and purification. The process begins with antibody sequences being entered into Twist’s eCommerce ordering platform, where bioinformatic screening and gene scoring is used to filter out potentially non-viable sequences. From there, synthetic DNA is generated, which is either cloned into one of Twist’s IgG scaffold vectors, or a vector of the customer’s choice. Twist’s silicon-based DNA synthesis platform enables the simultaneous production of up to thousands of antibody genes, which enables flexible production of tens to thousands of distinct antibodies. The antibodies are sequenced to ensure that the precise order has been cloned, every time. These antibodies are then produced in HEK293 cells, resin purified, and are usually delivered within 35 business days of ordering.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation the expected ability of Twist High Throughput Antibody Production to increase the efficiency of antibody discovery and optimization programs, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005314/en/